Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK521 in Advanced Solid Tumors with Malignant Ascites
NCT07561437Phase 1Recruiting
- Sponsor
- Base Therapeutics
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of NK521 in solid tumor (advanced stage) and malignant ascites (2 arms), sponsored by Base Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events and dose-limiting toxicities at 24 months. Started Mar 2026; status: recruiting.
02
Drugs
NK521
03
Conditions
solid tumor (advanced stage)malignant ascites
Beyond the preview
Go deeper on NCT07561437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07561437.